Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: Is there a racial difference? [4]

Annals of Oncology

Volumn 17, Issue 7, 2006, Pages 1175-1176

  Yoneda, K ^a   Tanji, Y ^a   Okishiro, M ^a   Taguchi, T ^a   Tamaki, Y ^a   Noguchi, S ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; AROMATASE INHIBITOR; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; ESTROGEN; ESTROGEN RECEPTOR; OSTEOCALCIN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; BONE DENSITY; BONE DISEASE; BONE TURNOVER; BREAST CANCER; CANCER ADJUVANT THERAPY; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; ESTROGEN BLOOD LEVEL; FEMALE; FEMUR NECK; HUMAN; LETTER; LUMBAR SPINE; MASTECTOMY; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RACE DIFFERENCE;

EID: 33745603475     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj128     Document Type: Letter

References (4)

1. Baum M, Budzar AU, Cuzick J et al. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
2. Eastell R, Adams J. Results of the Arimidex (anastrozole, A), tamoxifen (T), alone or in combination (ATAC) trial: Effects on bone mineral density (BMD) and bone turnover (ATAC Trialists' Group). Ann Oncol 2002; 13 (Suppl 5): 32 (Abstr 113OPD).
3. Ito M, Lang TF, Jergas M et al. Spinal trabecular bone loss and fracture in American and Japanese women. Calcif Tissue Int 1997; 61: 123-128.
4. Shimizu H, Ross RK, Bernstein L et al. Serum oestrogen levels in postmenopausal women: Comparison of American whites and Japanese in Japan. Br J Cancer 1990; 62: 451-453.